Crystallographic and kinetic methods have been used to characterize a site-specific variant of yeast enolase in which Ser 39 in the active-site flap has been changed to Ala. In the wild-type enzyme, the carbonyl and hydroxyl groups of Ser 39 chelate the second equivalent of divalent metal ion, effectively anchoring the flap over the fully liganded active site. With Mg(2+) as the activating cation, S39A enolase has <0.01% of wild-type activity as reported previously [J.M. Brewer, C.V. Glover, M.J. Holland, L. Lebioda, Biochim. Biophys. Acta 1383 (2) (1998) 351-355]. Measurements of (2)H kinetic isotope effects indicate that the proton abstraction from 2-phosphoglycerate (2-PGA) is significantly rate determining. Analysis of the isotope effects provides information on the relative rates of formation and breakdown of the enolate intermediate. Moreover, assays with different species of divalent metal ions reveal that with S39A enolase (unlike the case of wild-type enolase), more electrophilic metal ions promote higher activities. The kinetic results with the S39A variant support the notions that a rate-limiting product release lowers the activity of wild-type enolase with more electrophilic metal ions and that the metal ions are used to acidify the C2-proton of 2-PGA. The S39A enolase was co-crystallized with Mg(2+) and the inhibitor phosphonoacetohydroxamate (PhAH). The structure was solved and refined at a resolution of 2.1 A. The structure confirms the conjecture that the active-site flap is opened in the mutant protein. PhAH chelates to both Mg ions as in the corresponding structure of the wild-type complex. Positions of the side chains of catalytic groups, Lys 345 and Glu 211, and of "auxiliary" residues Glu 168 and Lys 396 are virtually unchanged relative to the complex with the wild-type protein. His 159, which hydrogen bonds to the phosphonate oxygens in the wild-type complex, is 5.7 A from the closest phosphonate oxygen, and the loop (154-166) containing His 159 is shifted away from the active center. A peripheral loop, Glu 251-Gly 275, also moves to open access to the active site.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-9861(02)00024-3DOI Listing

Publication Analysis

Top Keywords

active-site flap
8
functional structural
4
structural changes
4
changes serine
4
serine alanine
4
alanine mutation
4
mutation active-site
4
flap enolase
4
enolase crystallographic
4
crystallographic kinetic
4

Similar Publications

Hidradenitis Suppurativa: Radical Surgical Excisions with Staged Reconstructions: A Single-Surgeon Retrospective Review of 71 Patients.

Adv Skin Wound Care

January 2025

Abigail C. Judge, BS, is Medical Student, School of Medicine, Yale University, New Haven, Connecticut, United States. Amir H. Tahernia, MD, is Surgeon, Olympia Medical Center and Cedars-Sinai Medical Center, Los Angeles, California.

Background: Hidradenitis suppurativa is a chronic, inflammatory disease involving the pilosebaceous unit of apocrine gland-bearing skin. Wide surgical excision, wherein margins extend beyond active lesions, is considered curative.

Objective: To evaluate the safety and efficacy of wide surgical excision in the treatment of hidradenitis suppurativa.

View Article and Find Full Text PDF

Dyslipidemia, an imbalance in blood lipid levels, is a frequent complication of type 2 diabetes mellitus (DM2) and heightens the risk of cardiovascular diseases (CVDs). Statins, which inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, are potent competitive inhibitors that reduce plasma cholesterol levels. However, individual responses to statins can vary markedly, possibly due to genetic variations in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene.

View Article and Find Full Text PDF

Adhesions in the deep infrapatellar region may occur as iatrogenic complications (e.g., after bone-patellar tendon-bone grafting), as part of arthrofibrosis or infrapatellar contracture syndrome, or owing to specific diseases such as Osgood-Schlatter disease.

View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a serious neurodegenerative disorder marked by amyloid-beta plaques and neurofibrillary tangles, and it's primarily initiated by the action of the enzyme BACE1 on amyloid precursor protein (APP).
  • Researchers have discovered a small molecule that appears to effectively inhibit BACE1 by fitting well into its active site, outperforming the known drug Umibecestat (CNP-520) in terms of binding orientation and blocking the enzyme's activity.
  • The study utilized advanced techniques like virtual high-throughput screening and molecular dynamics simulations to identify and analyze potential drug leads for AD treatment, ultimately suggesting a promising new inhibitor for further development.
View Article and Find Full Text PDF

Exploring the conformational space of the mobile flap in Sporosarcina pasteurii urease by cryo-electron microscopy.

Int J Biol Macromol

December 2024

Department of Agricultural, Food and Environmental Sciences, Polytechnic University of Marche, I-60131 Ancona, Italy. Electronic address:

To fully understand enzymatic dynamics, it is essential to explore the complete conformational space of a biological catalyst. The catalytic mechanism of the nickel-dependent urease, the most efficient enzyme known, holds significant relevance for medical, pharmaceutical, and agro-environmental applications. A critical aspect of urease function is the conformational change of a helix-turn-helix motif that covers the active site cavity, known as the mobile flap.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!